Suppr超能文献

劳拉西泮的临床药代动力学:综述

Clinical pharmacokinetics of lorazepam: a review.

作者信息

Kyriakopoulos A A, Greenblatt D J, Shader R I

出版信息

J Clin Psychiatry. 1978 Oct;39(10 Pt 2):16-23.

PMID:30762
Abstract

The clinical pharmacokinetics of lorazepam, a 3-hydroxy, 1,4-benzodiazepine, indicate that it is rapidly and readily absorbed, reaching peak concentrations in the blood proportional to the dose approximately 2 hours after oral administration. Blood levels decline thereafter, with an elimination half-life of about 12 hrs. Conjugation with glucuronic acid to form inactive lorazepam glucuronide is the major metabolic pathway. Seventy (70) to 75% of the administered dose is excreted as the glucuronide conjugate in the urine. On multiple-dose regimens, steady state blood levels directly proportional to the daily dose occur within 2--3 days and are maintained after several months of continuous treatment. The active drug and the glucuronide conjugate are completely eliminated from the blood within 1 week following the last dose.

摘要

劳拉西泮是一种3-羟基-1,4-苯二氮䓬类药物,其临床药代动力学表明,该药吸收迅速且容易,口服给药后约2小时血药浓度达到峰值,与剂量成正比。此后血药浓度下降,消除半衰期约为12小时。与葡萄糖醛酸结合形成无活性的劳拉西泮葡萄糖醛酸苷是主要代谢途径。给药剂量的70%至75%以葡萄糖醛酸苷结合物形式经尿液排泄。在多剂量给药方案中,稳态血药浓度与日剂量成正比,在2至3天内达到,并在持续治疗数月后维持。最后一剂后1周内,活性药物和葡萄糖醛酸苷结合物从血液中完全清除。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验